Aroa Biosurgery Ltd
ASX:ARX

Watchlist Manager
Aroa Biosurgery Ltd Logo
Aroa Biosurgery Ltd
ASX:ARX
Watchlist
Price: 0.74 AUD 8.82%
Market Cap: 255.2m AUD
Have any thoughts about
Aroa Biosurgery Ltd?
Write Note

Gross Margin
Aroa Biosurgery Ltd

86.6%
Current
82%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
86.6%
=
Gross Profit
66.1m
/
Revenue
76.4m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
NZ
Aroa Biosurgery Ltd
ASX:ARX
255.2m AUD
87%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
318.1B USD
67%
US
Amgen Inc
NASDAQ:AMGN
142.2B USD
60%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
78%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD
86%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
135.7B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
36.2B EUR
89%
Country NZ
Market Cap 255.2m AUD
Gross Margin
87%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 318.1B USD
Gross Margin
67%
Country US
Market Cap 142.2B USD
Gross Margin
60%
Country US
Market Cap 117.1B USD
Gross Margin
78%
Country US
Market Cap 105.2B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.7B AUD
Gross Margin
52%
Country US
Market Cap 78.7B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36.2B EUR
Gross Margin
89%
No Stocks Found

Aroa Biosurgery Ltd
Glance View

Market Cap
255.2m AUD
Industry
Biotechnology

Aroa Biosurgery Ltd. engages in the development of products for wound care and soft tissue regeneration. The firm is engaged in commercializing regenerative tissue substitutes for medical conditions where impaired healing leads to serious consequences for patients. The company designs and manufactures medical products which enable surgeons and clinicians to repair serious tissue injuries. The Company’s solutions include Endoform platform, Wound Care Portfolio and Reinforced Bioscaffolds. The Endoform platform is a building block for developing a range of regenerative tissue substitutes to assist with tissue repair and healing. Its wound care products comprise extracellular matrix to manage acute and chronic wounds. The Reinforced Bioscaffolds combine the biologics and synthetics to address the surgical ventral hernia repair solutions.

ARX Intrinsic Value
1.18 AUD
Undervaluation 37%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
86.6%
=
Gross Profit
66.1m
/
Revenue
76.4m
What is the Gross Margin of Aroa Biosurgery Ltd?

Based on Aroa Biosurgery Ltd's most recent financial statements, the company has Gross Margin of 86.6%.